Early Screening and Precision Monitoring of Cancer

 Microfluidic CTC Capture Technology 

Current industry challenges: 

  • Cancer patients have very few CTCs in the blood (10-100/ml), while the number of blood cells is very large (109/ml). Identified by physical properties of the CTC is lacking of precision, and the use of only EpCAM or Folic Acid Receptor antigens for cancer cell identification has many problems, since not all CTCs have the same surface biomarker.

Our solution: 

  • Cellomics's microfluidic CTC capture technology combines the physical and biological properties of CTCs to further improve capture efficiency and sensitivity, which utilizes novel microfluidic structures and broad-spectrum cancer cell surface biomarker for enrichment and characterization of CTCs. It provides convenient operating conditions for single-cell analysis like gene mutation detection, whole-genome sequencing, and subsequent in vitro culture and drug sensitivity assessment.

 Microfluidic ddPCR Technology  

Current industry challenges: 


  • The detection of ctDNA/microRNAs by liquid biopsy requires high sensitivity technologies such as digital PCR and next-generation sequencing (NGS). Digital PCR is an absolute quantitative method for nucleic acid molecules, which is suitable for the detection of target mutations at 1% sensitivity. However, the sensitivity for liquid biopsy requires about 0.01% for early screening of tumors. Therefore, more sensitive digital PCR systems with greater dynamic range and specificity are needed.



Our solution: 


  • Cellomics microfluidic digital PCR technology, integrating microdroplet technology and fluorescent PCR, can produce 80,000 homogeneous droplets in the chip to achieve single-copy molecular detection with more accurate and digital signal. It can detect ctDNA/microRNAs for liquid biopsy and is suitable for early screening, drug resistance detection and therapeutic effect monitoring.



Digital PCR Chip Feature:

  • Data points as high as 100,000: high confidence, conducive to rare mutation detection, dynamic range as high as 10 ^ 6;
  • Independent patented technology, chip cost is lower;
  • High throughput: up to 5 fluorescence detection channels;
  • Easy to operate: in-situ generation, in-situ reaction; in-situ reading of data

BoosterTM PCR Reaction System

  • Special amplification promoter, amplification efficiency can be as high as 95-100%.Improve the signal-to-noise ratio, sensitivity and accuracy of PCR reaction

AimplifyTM Single Base Detection Technology

  • Lock Nucleic Acid (LNA) and Allele Specific Amplification (ASA)LNA decreases the flexibility of ribose structure, increases the stability of DNA structure, regulates the reaction of PCR and enhances the sequence specificity.ASA increases the specificity and sensitivity of detection reagents


Company Profile

Enterprise Culture

Organizational Structure

Research Leader

Team Elegant Demeanour

Honor & Qualification

Investment & Cooperation










Patient Story 

Research Results

Enterprise Dynamic

Latest Information

 WeChat Public Number

Copyright @ Cellomics All Rights Reserved  Email:info@cellomicsbio.com  Tel:+86-0755-28378001